

## **RYBELSUS – CHANGE IN FORMULATION, DOSING AND TABLET SIZE**

Please refer to the [MHRA Drug Safety Update Rybelsus® \(semaglutide tablets\): transition to new formulation and risk of medication error, December 2025](#)

Novo Nordisk has revised the formulation of Rybelsus.

The tablet size has been reduced and dose altered to allow it to be easier for patients to swallow, while still maintaining the equivalent efficacy and safety.

**The new strengths of Rybelsus will be 1.5mg, 4mg and 9mg.**

<b>RYBELSUS® Previous Formulation</b> (one oval tablet)	Bioequivalent	<b>RYBELSUS® New Formulation</b> (one round tablet)
3 mg (starting dose)	=	1.5 mg (starting dose)
7 mg (maintenance dose)	=	4 mg (maintenance dose)
14 mg (maintenance dose)	=	9 mg (maintenance dose)

From October 25 the new formulation should be available on the prescribing systems, however there is no definite date for when this will occur as this is dependant on the prescribing system updates and at this point it is not available on the VISION system.

Sufficient supplies of the new formulation have been assured.

**The current strengths, 3mg, 7mg and 14mg will be available until at least January 2026, so there should be a 3 month period for a switch over of patients prescribed these.**

### **Suggested timelines :**

#### **From 1/11/26**

- **new start patients can be prescribed the new formulations of Rybelsus as this will be available on the VISION/EMIS systems and the supply chain should be confirmed**
- **patients currently prescribed Rybelsus can be switched over**
- **it will be up to each practice how they decided to action this and inform patients**
- **it may be an opportunity to review patient compliance, dosing and continued benefit**
- **switches require to be completed by the end of January 2026**

Novo Nordisk have useful patient information guides if GP practices decide to utilise these either electronically or in a paper format ( these can be requested from Novo Nordisk)

[Rybelsus patient information leaflet](#)

**Community Pharmacies should be able to access all strengths of Rybelsus during this time and no changes to prescriptions should be requested due to supply issues.**

Gillian Booth / Cameron Munro, October 2025

Updated by Claire James, Lead Pharmacist Medicines Information to include MHRA advice, December 2025